Apellis Pharmaceuticals, Inc.
APLSDelisted May 14, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001492422
Apellis Pharmaceuticals, Inc. was delisted on May 14, 2026; its insiders filed their last Form 4 on May 14, 2026; 324 institutions reported holding it in 13F filings for Q1 2026, worth $5.56B in total; Soros Fund Management was the only superinvestor holding it.
Q2 2026 vs. Q1 2026
How the institutions holding Apellis Pharmaceuticals, Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Of which not filed for Q2 2026 | Q2 2026 | Change |
|---|---|---|---|---|
| Holders | 324 | 6 | 1 | −317 |
| Shares | 140.4M | 321.8K | 248 | −140.1M (−100.0%) |
| Value | $5.56B | $12.9M | $10.2K | −$5.55B (−100.0%) |
6 institutions that held it in Q1 2026 haven't filed for Q2 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (0)
Institutions that held Apellis Pharmaceuticals, Inc. at the end of Q2 2026 but not at the end of Q1 2026.
None.
Sold out (317)
Institutions that held Apellis Pharmaceuticals, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
Showing the largest 100 of 317 by value.
Not filed for Q2 2026 yet (6)
Institutions that held Apellis Pharmaceuticals, Inc. at the end of Q1 2026 and haven't filed a 13F for Q2 2026. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Janus Henderson Group PLC | 252,130 | $10.1M |
| CIBRA Capital Ltd | 50,000 | $2.01M |
| CWM, LLC | 11,403 | $458.7K |
| BCK Capital Management LP | 8,000 | $321.8K |
| Evelyn Partners Investment Management LLP | 150 | $6.04K |
| Sofos Investments, Inc. | 100 | $4.02K |